Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Eletriptan commercial · 1 trial · 1 indication
AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).
Area under the plasma concentration-time curve from time zero (pre-dose) to the time of the last measurable concentration (AUClast).
| Arm | Type | Description |
|---|---|---|
| Treatment A | EXPERIMENTAL | 1 X 20 mg eletriptan |
| Treatment B | EXPERIMENTAL | 1 X 40 mg eletriptan |
| Treatment C | EXPERIMENTAL | 2 X 40 mg eletriptan |
| Treatment D | EXPERIMENTAL | 1 X 40 mg tablet given 2 hr after initial 1 X 40 mg tablet dose |
| Name | Type | Description |
|---|---|---|
| Eletriptan commercial tablet | DRUG | 20 mg tablet, single dose |
Inclusion Criteria: * healthy male subjects, 18-55 years old * Body Mass Index (BMI) of 17.5 to 30.5 kg/m2 * provide informed consent Exclusion Criteria: * blood pressure \>140/90 mm Hg * any condition possibly affecting drug absorption * positive urine drug screen
Eletriptan commercial is a small molecule being studied for use in healthy individuals. It is currently in Phase 1 clinical development, with one completed trial focused on its pharmacokinetics in healthy Korean males. The drug is being developed by Pfizer, Inc. (PFE).
Eletriptan commercial is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE. The company is conducting clinical research on this small molecule, which is currently in Phase 1 development for use in healthy individuals.
Eletriptan commercial is in Phase 1 clinical development. It is an investigational drug, not yet approved, and is being studied for its pharmacokinetics in healthy volunteers. One Phase 1 trial has been completed, involving 16 participants.
Eletriptan commercial has one completed clinical trial, NCT01139515, titled 'Eletriptan Pharmacokinetics In Korean Males.' This Phase 1 study enrolled 16 healthy male participants in South Korea, with a minimum age of 18 years. The trial was controlled but not double-blind.
Eletriptan commercial is a formulation of eletriptan, a small molecule being studied by Pfizer. The 'commercial' designation likely refers to the commercial-grade version of the drug. It is currently in Phase 1 development for healthy individuals, with one completed pharmacokinetic trial.